DISEASE CHARACTERISTICS:

• Histologically confirmed mantle cell lymphoma of any stage with at least 1 of the following:

  • Immunophenotype with expression of CD5 and CD19 and absence of CD23
  • Cytogenetic analysis with presence of t(11;14)
  • Overexpression of cyclin D1
  • Rearrangement of BCL1 gene

• Bone marrow biopsy required

  • No needle or core biopsy as sole means of diagnosis

• First remission allowed if at least 1 of the following poor prognostic characteristics present:

  • International Prognostic Index (IPI) score higher than 1 defined by the following risk factors:

    • Performance status higher than 1
    • Elevated LDH
    • Presence of more than 1 extranodal site
    • Stage III or IV disease
  • Blastic variant of mantle cell lymphoma*
  • Complex karyotypes (i.e., cytogenetic abnormalities different from or in addition to t(11;14)*
  • Proliferative index more than 10%*
  • Presence of p53 mutations NOTE: *Regardless of IPI score

• Failure of initial therapy with anthracycline-containing regimen allowed

  • Failure to achieve clinical complete remission after initial therapy OR
  • Recurrent disease after initial therapy

• HLA matched (6/6) sibling donor by serologic typing (A, B, or DR)

  • Any age
  • No syngeneic (identical twin) donor
• No active CNS lymphoma

PATIENT CHARACTERISTICS:

Age:

• Under 60

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2 mg/dL
• AST and ALT no greater than 3 times upper limit of normal

Renal:

• Creatinine less than 2 mg/dL

Pulmonary:

• DLCO at least 40%
• No symptomatic pulmonary disease

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior bone marrow transplantation

Chemotherapy:

• See Disease Characteristics
• No more than 2 prior chemotherapy regimens
• No other concurrent chemotherapy

Endocrine therapy:

• No concurrent hormonal therapy

Radiotherapy:

• No concurrent radiotherapy to bulky sites

Surgery:

• See Disease Characteristics